TNGX Tango Therapeutics
Tango Therapeutics earnings company data as of 12:25 PM ET 11/17
- 0 of 1 EPS beats
History
1 period, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 9 Nov | EPS | -0.35 | -0.39 | Miss |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by TNGX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- $7.4M sold by 3 insiders under 10b5-1 plans
-
John B. Ketchum DirectorPlanned sale$80K 3,333 shares at $24.08 13% of stakeTraded Nov 17 Filed Nov 19
-
Adam Crystal President, R&DPlanned sale$125K 5,000 shares at $25.00 4.1% of stakeTraded Nov 11 Filed Nov 13
-
Adam Crystal President, R&DPlanned sale$112K 5,000 shares at $22.42 4.1% of stakeTraded Nov 2 Filed Nov 4
-
Jessica Newcomb Principal Accounting OfficerPlanned sale$158K 7,031 shares at $22.42 12% of stakeTraded Nov 2 Filed Nov 4
-
Adam Crystal President, R&DPlanned sale$661K 27,000 shares at $24.47 19% of stakeTraded Oct 1 Filed Oct 5
-
Jessica Newcomb Principal Accounting OfficerPlanned sale$199K 8,200 shares at $24.22 12% of stakeTraded Sep 22 Filed Sep 24
-
Adam Crystal President, R&DPlanned sale$604K 27,000 shares at $22.37 19% of stakeTraded Sep 1 Filed Sep 3
-
Adam Crystal President, R&DPlanned sale$736K 27,000 shares at $27.24 19% of stakeTraded Aug 3 Filed Aug 5
-
Adam Crystal President, R&DPlanned sale$799K 27,000 shares at $29.59 19% of stakeTraded Jul 1 Filed Jul 2
-
Adam Crystal President, R&DPlanned sale$618K 27,000 shares at $22.87 19% of stakeTraded Jun 1 Filed Jun 3
-
Adam Crystal President, R&DPlanned sale$573K 27,000 shares at $21.23 19% of stakeTraded May 1 Filed May 5
-
Adam Crystal President, R&DPlanned sale$962K 38,460 shares at $25.00 26% of stakeTraded Apr 15 Filed Apr 16
-
Adam Crystal President, R&DPlanned sale$572K 27,000 shares at $21.20 19% of stakeTraded Apr 1 Filed Apr 2
-
Adam Crystal President, R&DPlanned sale$241K 12,000 shares at $20.11 9.6% of stakeTraded Mar 25 Filed Mar 27
-
Adam Crystal President, R&DPlanned sale$304K 20,251 shares at $15.00 15% of stakeTraded Mar 5 Filed Mar 9
Also filed in the last 12 months, not counted as buying or selling: 12 stock grants, 11 option exercises, and 6 sales to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K/A | 5.02,7.01,9.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 5.02,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon
- Financial Intelligence, Revised Ed. View on Amazon